# Roberto Pili

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5206065/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 50 papers | 3,122 citations | 201674 27 h-index | 197818 49 g-index |
| 51 all docs | 51 docs citations | 51 times ranked | 5396 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | Combined inhibition of Refâ€1 and STAT3 leads to synergistic tumour inhibition in multiple cancers using 3D and in vivo tumour coâ€culture models. Journal of Cellular and Molecular Medicine, 2021, 25, 784-800. | 3.6 | 9 |
| 2 | Phase I study of the mTOR inhibitor everolimus in combination with the histone deacetylase inhibitor panobinostat in patients with advanced clear cell renal cell carcinoma. Investigational New Drugs, 2020, 38, 1108-1116. | 2.6 | 11 |
| 3 | Epigenetic Dysregulation in Advanced Kidney Cancer. Cancer Journal (Sudbury, Mass ), 2020, 26, 399-406. | 2.0 | 3 |
| 4 | Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer. British Journal of Cancer, 2020, 123, 1590-1598. | 6.4 | 57 |
| 5 | Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma. Molecular Cancer Therapeutics, 2020, 19, 147-156. | 4.1 | 10 |
| 6 | CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors. JCO Precision Oncology, 2020, 4, 370-381. | 3.0 | 138 |
| 7 | Antitumor Activity and Mechanistic Characterization of APE1/Ref-1 Inhibitors in Bladder Cancer. Molecular Cancer Therapeutics, 2019, 18, 1947-1960. | 4.1 | 29 |
| 8 | Immunomodulation by HDAC inhibition: Results from a phase Ib study with vorinostat and pembrolizumab in metastatic urothelial, renal, and prostate carcinoma patients.. Journal of Clinical Oncology, 2019, 37, 2572-2572. | 1.6 | 10 |
| 9 | A phase I/II trial of pazopanib alternating with bevacizumab in treatment-naÃ¯ve metastatic clear cell renal cell carcinoma (CCRCC) patients: Phase I results.. Journal of Clinical Oncology, 2019, 37, 561-561. | 1.6 | 1 |
| 10 | Therapeutic Targeting of Sunitinib-Induced AR Phosphorylation in Renal Cell Carcinoma. Cancer Research, 2018, 78, 2886-2896. | 0.9 | 27 |
| 11 | Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer. Free Radical Biology and Medicine, 2018, 115, 447-457. | 2.9 | 65 |
| 12 | Phase I Study of Dalteparin in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Carcinoma. Clinical Genitourinary Cancer, 2018, 16, e1-e9. | 1.9 | 11 |
| 13 | Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2018, 4, 944. | 7.1 | 86 |
| 14 | Low-protein diet in cancer: ready for prime time?. Nature Reviews Endocrinology, 2018, 14, 384-386. | 9.6 | 3 |
| 15 | Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. Clinical Cancer Research, 2018, 24, 5977-5989. | 7.0 | 58 |
| 16 | Plasmacytoid urothelial carcinoma: A clinicopathological study.. Journal of Clinical Oncology, 2018, 36, 482-482. | 1.6 | 5 |
| 17 | Clinical features and survival outcomes in a prospective spontaneous regression (SR) protocol of renal cell carcinoma (RCC) and melanoma (M) patients.. Journal of Clinical Oncology, 2018, 36, e16585-e16585. | 1.6 | 0 |
| 18 | Unclassified Renal Cell Carcinoma With Significant Response to Nivolumab. Clinical Genitourinary Cancer, 2017, 15, e517-e519. | 1.9 | 5 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Combination of the histone deacetylase inhibitor vorinostat with bevacizumab in patients with clear-cell renal cell carcinoma: a multicentre, single-arm phase I/II clinical trial. British Journal of Cancer, 2017, 116, 874-883. | 6.4 | 78 |
| 20 | A Randomized Phase II Study to Determine the Effect of 2 Different Doses of Aflibercept in Patients With Metastatic Renal Cell Carcinoma (ECOG-ACRIN [E4805]). Clinical Genitourinary Cancer, 2017, 15, 642-651.e1. | 1.9 | 1 |
| 21 | EZH2 Modifies Sunitinib Resistance in Renal Cell Carcinoma by Kinome Reprogramming. Cancer Research, 2017, 77, 6651-6666. | 0.9 | 66 |
| 22 | Immunomodulation by Entinostat in Renal Cell Carcinoma Patients Receiving High-Dose Interleukin 2: A Multicenter, Single-Arm, Phase I/II Trial (NCI-CTEP#7870). Clinical Cancer Research, 2017, 23, 7199-7208. | 7.0 | 68 |
| 23 | Preservation of truncal genomic alterations in clear cell and papillary renal cell carcinomas with sarcomatoid features: An intraâ€•and intertumoral, multifocal fluorescence in situ hybridization analysis reveals limited genetic heterogeneity. Molecular Carcinogenesis, 2017, 56, 2527-2537. | 2.7 | 5 |
| 24 | Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clinical Cancer Research, 2017, 23, 5187-5201. | 7.0 | 288 |
| 25 | Real-Time Multiplex Kinase Phosphorylation Sensors in Living Cells. ACS Sensors, 2017, 2, 1225-1230. | 7.8 | 10 |
| 26 | Selenomethionine and methyl selenocysteine: multiple-dose pharmacokinetics in selenium-replete men. Oncotarget, 2017, 8, 26312-26322. | 1.8 | 22 |
| 27 | Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 2636-2643. | 1.6 | 77 |
| 28 | Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 38 | 13.7 | 529 |
| 29 | Histone deacetylase inhibitors as immunomodulators in cancer therapeutics. Epigenomics, 2016, 8, 415-428. | 2.1 | 60 |
| 30 | Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2016, 22, 1356-1363. | 7.0 | 71 |
| 31 | Combination Strategy Targeting VEGF and HGF/c-met in Human Renal Cell Carcinoma Models. Molecular Cancer Therapeutics, 2015, 14, 101-110. | 4.1 | 82 |
| 32 | Sunitinib Dose Escalation Overcomes Transient Resistance in Clear Cell Renal Cell Carcinoma and Is Associated with Epigenetic Modifications. Molecular Cancer Therapeutics, 2015, 14, 513-522. | 4.1 | 64 |
| 33 | Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer. Oncotarget, 2015, 6, 24376-24392. | 1.8 | 18 |
| 34 | Restriction of dietary protein decreases mTORC1 in tumors and somatic tissues of a tumor-bearing mouse xenograft model. Oncotarget, 2015, 6, 31233-31240. | 1.8 | 55 |
| 35 | Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer. PLoS ONE, 2014, 9, e103680. | 2.5 | 11 |
| 36 | Mechanism of action and clinical activity of tasquinimod in castrate-resistant prostate cancer. OncoTargets and Therapy, 2014, 7, 223. | 2.0 | 16 |

| # | Article | IF | Citations |
|---|---|---|---|
| 37 | Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy. Journal of Visualized Experiments, 2014, , . | 0.3 | 15 |
| 38 | Dll4 Blockade Potentiates the Anti-Tumor Effects of VEGF Inhibition in Renal Cell Carcinoma Patient-Derived Xenografts. PLoS ONE, 2014, 9, e112371. | 2.5 | 45 |
| 39 | Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature. Oncoscience, 2014, 1, 844-853. | 2.2 | 26 |
| 40 | Generation of a syngeneic orthotopic transplant model of prostate cancer metastasis. Oncoscience, 2014, 1, 609-613. | 2.2 | 10 |
| 41 | Dietary protein restriction inhibits tumor growth in human xenograft models of prostate and breast cancer. Oncotarget, 2013, 4, 2451-2461. | 1.8 | 110 |
| 42 | Vascular Disruption in Combination with mTOR Inhibition in Renal Cell Carcinoma. Molecular Cancer Therapeutics, 2012, 11, 383-392. | 4.1 | 22 |
| 43 | Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy. OncoImmunology, 2012, 1, 948-950. | 4.6 | 48 |
| 44 | Class I Histone Deacetylase Inhibitor Entinostat Suppresses Regulatory T Cells and Enhances Immunotherapies in Renal and Prostate Cancer Models. PLoS ONE, 2012, 7, e30815. | 2.5 | 158 |
| 45 | Reversible Epithelial to Mesenchymal Transition and Acquired Resistance to Sunitinib in Patients with Renal Cell Carcinoma: Evidence from a Xenograft Study. Molecular Cancer Therapeutics, 2010, 9, 1525-1535. | 4.1 | 160 |
| 46 | Combination Strategy Targeting the Hypoxia Inducible Factor-1Î± with Mammalian Target of Rapamycin and Histone Deacetylase Inhibitors. Clinical Cancer Research, 2008, 14, 3589-3597. | 7.0 | 105 |
| 47 | Platelets Take Up the Monoclonal Antibody Bevacizumab. Clinical Cancer Research, 2007, 13, 5341-5347. | 7.0 | 105 |
| 48 | Vascular Endothelial Growth Factor Trap Blocks Tumor Growth, Metastasis Formation, and Vascular Leakage in an Orthotopic Murine Renal Cell Cancer Model. Clinical Cancer Research, 2007, 13, 4201-4208. | 7.0 | 111 |
| 49 | Synergistic In vivo Antitumor Effect of the Histone Deacetylase Inhibitor MS-275 in Combination with Interleukin 2 in a Murine Model of Renal Cell Carcinoma. Clinical Cancer Research, 2007, 13, 4538-4546. | 7.0 | 82 |
| 50 | Epigenetic Modulation of Retinoic Acid Receptor Î²2 by the Histone Deacetylase Inhibitor MS-275 in Human Renal Cell Carcinoma. Clinical Cancer Research, 2005, 11, 3535-3542. | 7.0 | 76 |